Beam Therapeutics Inc

NASDAQ:BEAM   11:31:04 AM EDT
80.01
+1.35 (+1.72%)
Products

Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies

Published: 11/12/2021 12:58 GMT
Beam Therapeutics Inc (BEAM) - Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-cd5 Car T-cell Investigational Therapies for T-cell Malignancies.
Beam Therapeutics Inc - Multiplexed Base Editing Resulted in Anti-cd5 Car T Cells With 94-98% Editing Efficiency at All 5 Target Loci.
Beam Therapeutics Inc - Multiplexed Base Editing Resulted in Anti-cd5 Car T Cells With Transduction Efficiency of Over 85%.
Beam Therapeutics Inc - Cd5 Knockout Improved Production of Combination of Proinflammatory Cytokines, Greater Than 300% Increase in Il-2 Production.
Beam Therapeutics Inc - Cd5 Knockout Improved in Vivo Efficacy of Anti-cd5 Car T Cells in a Xenograft Mouse Model of T-all Compared to Unedited Cells.